MA32904B1 - COMPOUNDS OF PURINE - Google Patents

COMPOUNDS OF PURINE

Info

Publication number
MA32904B1
MA32904B1 MA33947A MA33947A MA32904B1 MA 32904 B1 MA32904 B1 MA 32904B1 MA 33947 A MA33947 A MA 33947A MA 33947 A MA33947 A MA 33947A MA 32904 B1 MA32904 B1 MA 32904B1
Authority
MA
Morocco
Prior art keywords
purine
compounds
pain
compound
formula
Prior art date
Application number
MA33947A
Other languages
Arabic (ar)
French (fr)
Inventor
Peter Charles Astles
Rossella Guidetti
Sean Patrick Hollinshead
Michael Wade Tidwell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA32904B1 publication Critical patent/MA32904B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention porte sur un composé de formule et sur des compositions pharmaceutiques pour le traitement de la douleur.The invention relates to a compound of formula and to pharmaceutical compositions for the treatment of pain.

MA33947A 2008-12-18 2011-06-14 COMPOUNDS OF PURINE MA32904B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13858908P 2008-12-18 2008-12-18
PCT/US2009/067249 WO2010080306A1 (en) 2008-12-18 2009-12-09 Purine compounds

Publications (1)

Publication Number Publication Date
MA32904B1 true MA32904B1 (en) 2011-12-01

Family

ID=41719189

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33947A MA32904B1 (en) 2008-12-18 2011-06-14 COMPOUNDS OF PURINE

Country Status (29)

Country Link
US (1) US8252798B2 (en)
EP (1) EP2379555B1 (en)
JP (1) JP5559812B2 (en)
KR (1) KR101319630B1 (en)
CN (1) CN102256977B (en)
AR (1) AR075104A1 (en)
AU (1) AU2009335997B2 (en)
BR (1) BRPI0923195A2 (en)
CA (1) CA2746740C (en)
CL (1) CL2011001464A1 (en)
CO (1) CO6390101A2 (en)
CR (1) CR20110340A (en)
DO (1) DOP2011000196A (en)
EA (1) EA018386B1 (en)
EC (1) ECSP11011151A (en)
ES (1) ES2536880T3 (en)
HN (1) HN2011001700A (en)
IL (1) IL213167A (en)
MA (1) MA32904B1 (en)
MX (1) MX2011006442A (en)
NZ (1) NZ593088A (en)
PA (1) PA8851501A1 (en)
PE (1) PE20110999A1 (en)
SG (1) SG172253A1 (en)
TN (1) TN2011000291A1 (en)
TW (1) TWI376378B (en)
UA (1) UA104010C2 (en)
WO (1) WO2010080306A1 (en)
ZA (1) ZA201103943B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2754890C (en) * 2009-03-13 2018-01-16 Piet Herdewijn Bicyclic heterocycles
AR077991A1 (en) 2009-08-28 2011-10-05 Arena Pharm Inc CANNABINOID RECEIVER MODULATORS
WO2011113802A2 (en) * 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
AR080711A1 (en) 2010-03-31 2012-05-02 Lilly Co Eli PIPERAZIN-PURINA COMPOSITE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF PAIN
EP2552916B1 (en) * 2010-03-31 2014-05-21 Eli Lilly and Company Purine compounds used as cb2 agonists
MX2013003019A (en) 2010-09-15 2013-05-28 Hoffmann La Roche Azabenzothiazole compounds, compositions and methods of use.
MX2013005445A (en) 2010-11-19 2013-07-29 Hoffmann La Roche Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors.
DK3395812T3 (en) 2011-02-25 2022-11-28 Arena Pharm Inc Crystalline forms and methods for the preparation of fused azacycles (cannabinoid receptor modulators)
WO2012116277A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
PT3385252T (en) 2011-02-25 2022-11-03 Arena Pharm Inc Cannabinoid receptor modulators
CN103827115A (en) * 2011-09-20 2014-05-28 弗·哈夫曼-拉罗切有限公司 Imidazopyridine compounds, compositions and methods of use
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
BR112015003395A2 (en) * 2012-08-16 2017-07-04 Janssen Pharmaceutica Nv substituted pyrazoles as n-type calcium channel blockers
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP2991988B1 (en) * 2013-05-02 2017-05-31 F. Hoffmann-La Roche AG Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017052394A1 (en) * 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
WO2018137176A1 (en) * 2017-01-25 2018-08-02 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2017184412A1 (en) 2016-04-18 2017-10-26 Eli Lilly And Company Purine cannabinoid agonist for treating nonalcoholic steatohepatitis and fibrosis
WO2017181317A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2018119076A1 (en) * 2016-12-21 2018-06-28 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
WO2024017227A1 (en) * 2022-07-21 2024-01-25 长春金赛药业有限责任公司 Substituted fused ring cannabinoid receptor compound and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60260579A (en) 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd Purine derivative
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
NZ225447A (en) 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US7115741B2 (en) * 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
WO2005067546A2 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
CA2584278A1 (en) * 2004-10-22 2006-04-27 Pfizer Products Inc. Process for preparing purine compounds
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
EA031335B1 (en) * 2006-02-02 2018-12-28 Миллениум Фармасьютикалз, Инк. Pyrrolopyrimidine derivatives
EP2503890A4 (en) * 2009-11-24 2013-05-15 Glaxosmithkline Llc Azabenzimidazoles as fatty acid synthase inhibitors
AR080711A1 (en) * 2010-03-31 2012-05-02 Lilly Co Eli PIPERAZIN-PURINA COMPOSITE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF PAIN

Also Published As

Publication number Publication date
SG172253A1 (en) 2011-07-28
CR20110340A (en) 2011-09-16
KR20110084459A (en) 2011-07-22
US20100160288A1 (en) 2010-06-24
PA8851501A1 (en) 2010-07-27
CO6390101A2 (en) 2012-02-29
AR075104A1 (en) 2011-03-09
EP2379555A1 (en) 2011-10-26
JP5559812B2 (en) 2014-07-23
TN2011000291A1 (en) 2012-12-17
DOP2011000196A (en) 2011-10-31
JP2012512873A (en) 2012-06-07
MX2011006442A (en) 2011-07-19
ZA201103943B (en) 2012-11-28
ES2536880T3 (en) 2015-05-29
US8252798B2 (en) 2012-08-28
AU2009335997A1 (en) 2011-06-23
CN102256977B (en) 2014-04-16
CN102256977A (en) 2011-11-23
EA201170832A1 (en) 2011-12-30
TWI376378B (en) 2012-11-11
ECSP11011151A (en) 2011-07-29
CL2011001464A1 (en) 2012-01-20
TW201024296A (en) 2010-07-01
HN2011001700A (en) 2013-05-06
EA018386B1 (en) 2013-07-30
WO2010080306A1 (en) 2010-07-15
NZ593088A (en) 2012-12-21
AU2009335997B2 (en) 2012-05-10
KR101319630B1 (en) 2013-10-17
PE20110999A1 (en) 2012-01-16
CA2746740A1 (en) 2010-07-15
EP2379555B1 (en) 2015-02-25
UA104010C2 (en) 2013-12-25
IL213167A (en) 2013-11-28
IL213167A0 (en) 2011-07-31
BRPI0923195A2 (en) 2016-02-16
CA2746740C (en) 2014-01-14

Similar Documents

Publication Publication Date Title
MA32904B1 (en) COMPOUNDS OF PURINE
MA42410A (en) OXYSTEROLS AND THEIR METHODS OF USE
MA32171B1 (en) Heterocyclic formulations
MA37866B1 (en) Aza-indazole or diaza-indazole derivatives for the treatment of pain
MA33909B1 (en) Pyrolidine is adherent as syk inhibitors
PT2150530E (en) Substituted sulfonamide derivatives
MA33076B1 (en) USE OF A GAMMA SECRETASE INHIBITOR FOR THE TREATMENT OF CANCER
MA33224B1 (en) Proline derivatives as catecin inhibitors
MA33428B1 (en) Inducers of gpr119
IN2012DN02661A (en)
HUE037974T2 (en) Pharmaceutical compositions for treatment of parkinson's disease
MA31158B1 (en) Tricyclic compounds and their use as modifiers for glucocorticoid receptors.
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
TR201900199T4 (en) Immediate release pharmaceutical compositions containing oxycodone and naloxone.
MX2013004329A (en) Substituted 6-amino-nicotinamides as kcnq2/3 modulators.
UY31065A1 (en) CYCLIC HETEROCICLES
EA200600971A1 (en) APPLICATION OF SUBSTITUTED 2 - AMINOTHETRALINES FOR THE PREVENTION TREATMENT OF PARKINSON'S Disease
MA38810A1 (en) Inhibitors of rorc2 related methods of use
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MA32841B1 (en) Compounds of cyclondica dipseibeptides and their use as drugs
JO2999B1 (en) Tricyclic Compound And Pharmaceutical Use Therof
DE602007007934D1 (en) Imidazoazephinonverbindungen
MX2012007426A (en) Amino-heteroaryl derivatives as hcn blockers.
JO2820B1 (en) Combination of a Bisthiazolium Salt or a Precursor Thereof and Artemisinin or a Derivative Thereof for the Treatment of Severe Malaria
MA32902B1 (en) Arilcyclopropylacetamide derivatives are useful for the activation of glucokinase